Reversion of phenotypic fluoroquinolone resistance in Mycobacterium tuberculosis

Int J Tuberc Lung Dis. 2016 Sep;20(9):1276-7. doi: 10.5588/ijtld.16.0335.

Authors

Brandon Eilertson¹, Fernanda Maruri², Amondrea Blackman², Miguel Herrera³, Timothy R Sterling²

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, SUNY Downstate Medical Center, New York, NY, USA.
² Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Vanderbilt Tuberculosis Center, Vanderbilt University School of Medicine, USA.
³ Vanderbilt Technologies for Advanced Genomics, Vanderbilt University, Nashville, TN, USA. Brandon.Eilertson@Downstate.edu.

PMID: 27510259
DOI: 10.5588/ijtld.16.0335

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antitubercular Agents / pharmacology*
DNA Gyrase / genetics
Drug Resistance, Bacterial
Fluoroquinolones / pharmacology*
Humans
Male
Microbial Sensitivity Tests
Mycobacterium tuberculosis / drug effects*
Mycobacterium tuberculosis / isolation & purification
Tuberculosis / drug therapy
Tuberculosis / microbiology

Substances

Antitubercular Agents
Fluoroquinolones
DNA Gyrase